Neurocrine Biosciences Inc
(MIL:1NBIX)
€
135.8
(0%)
Market Cap: 13.21 Bil
Enterprise Value: 13.22 Bil
PE Ratio: 22.91
PB Ratio: 4.30
GF Score: 73/100 Neurocrine Biosciences, Inc. at Morgan Stanley Global Healthcare Conference Transcript
Sep 15, 2026 / 02:45PM GMT
Release Date Price:
€135.8
Sean Laaman
Morgan Stanley - Moderator
Good morning, everyone. I'm Sean Laaman, Head of US MidCap Biotech Equity Research here at Morgan Stanley. Before we commence, to make you aware of some important disclosures, see those disclosures at the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. And if you do have any questions, please reach out and ask all Morgan Stanley sales representative.
With that said, we have the pleasure of welcoming from Neurocrine Biosciences, their CEO, Kyle Gano, and from IR Todd Tushla. Welcome, gentlemen and thank you both for your time today.
Kyle Gano
Neurocrine Biosciences, Inc. - President, Chief Executive Officer, Director
Thank you.
Questions & Answers
Sean Laaman
Morgan Stanley - Moderator
Maybe just to kick off proceedings before we get into the heart of Neurocrine. Just a question, just a few general questions on the macro side
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot